ECM
NKTR icon

Endurant Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Endurant Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-527
Closed -$386K – 81
2018
Q2 		$386K Buy
+527
New +$608K 0.17% 58
2017
Q4 		– Sell
-7,287
Closed -$2.62M – 86
2017
Q3 		$2.62M Buy
7,287
+4,434
+155% +$1.39M 0.79% 46
2017
Q2 		$837K Buy
+2,853
New +$824K 0.24% 72

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Endurant Capital Management's NKTR Position: Q3 2018 in Review

Endurant Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 527 shares — an estimated $386K sold.

Endurant Capital Management first reported a position in NKTR in Q2 2017 and held it in 3 quarters. The position peaked at $2.62M in Q3 2017. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • Endurant Capital Management reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Endurant Capital Management sold 527 Nektar Therapeutics shares in Q3 2018, an estimated $386K.
  • Endurant Capital Management first reported a position in Nektar Therapeutics in Q2 2017 and held it in 3 quarters.
  • Endurant Capital Management's Nektar Therapeutics position peaked at $2.62M in Q3 2017.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.